Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | hypothetical protein | 0.0079 | 0.7736 | 1 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription factor | 0.0097 | 1 | 1 |
Schistosoma mansoni | jun-related protein | 0.0079 | 0.7736 | 1 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0041 | 0.3091 | 0.3091 |
Echinococcus multilocularis | nuclear factor of activated T cells 5 | 0.0085 | 0.8512 | 0.8512 |
Echinococcus granulosus | nuclear factor of activated T cells 5 | 0.0085 | 0.8512 | 0.8512 |
Echinococcus granulosus | jun protein | 0.0097 | 1 | 1 |
Echinococcus multilocularis | jun protein | 0.0097 | 1 | 1 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0041 | 0.3091 | 0.3091 |
Entamoeba histolytica | hypothetical protein | 0.0041 | 0.3091 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0094 | 0.9669 | 1 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0041 | 0.3091 | 0.3996 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription factor | 0.0097 | 1 | 1 |
Brugia malayi | hypothetical protein | 0.0076 | 0.7404 | 0.6243 |
Onchocerca volvulus | 0.0076 | 0.7404 | 0.5 | |
Schistosoma mansoni | hypothetical protein | 0.0041 | 0.3091 | 0.3996 |
Entamoeba histolytica | hypothetical protein | 0.0041 | 0.3091 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0041 | 0.3091 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0041 | 0.3091 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | = 190 uM | Ex vivo immunosuppressive activity in Drosophila larvae assessed as inhibition of IMD signaling pathway by beta-galactosidase reporter gene assay | ChEMBL. | 21334120 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.